| Outcome Measures: |
Primary: Overall Adverse Event Summary, To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks|Hypoglycemia, To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks|Diabetic Ketoacidosis (DKA), To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks|Vital Signs (Heart Rate), To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks|ECGs, To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks|Clinical Laboratory Measures, Urine Test Results (Any Marked Abnormality), To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks|Vital Signs (Blood Pressure), To evaluate safety and tolerability of long-term treatment (52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM with inadequate glycemic control under standard insulin therapy., From baseline to 52 weeks | Secondary: Adjusted Change From Baseline in HbA1c, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy., From baseline to 24/52 weeks|Adjusted Percent Change From Baseline in Total Daily Insulin Dose, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy., From baseline to 24/52 weeks|Adjusted Percent Change From Baseline in Body Weight, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy., From baseline to 24/52 weeks|Adjusted Change From Baseline in Glycoalbumin, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy., From baseline to 24/52 weeks|Adjusted Change From Baseline in Average Daily Glucose Measured by 6-point SMBG, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy., From baseline to 24/52 weeks|Adjusted Change From Baseline in Post-prandial Glucose Measured by 6-point SMBG, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin therapy., From baseline to 24/52 weeks|Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent Without Severe Hypoglycemia, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin, From baseline to 24/52 weeks|Proportion of Subjects Achieving HbA1c Reduction of 0.5 Percent, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin, From baseline to 24/52 weeks|Proportion of Subjects Achieving HbA1c < 7.0 Percent, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin, From baseline to 24/52 weeks|Adjusted Change From Baseline in SBP in Subjects With Baseline SBP/DBP >= 140/90 mmHg, To assess the efficacy of long-term treatment (24/52 weeks) of dapagliflozin 5mg and 10 mg in Japanese patients with T1DM inadequately controlled on insulin, From baseline to 24/52 weeks
|
| Locations: |
Research Site, Aizu Wakamatsu-shi, Japan|Research Site, Chuo-ku, Japan|Research Site, Fukuoka-shi, Japan|Research Site, Fukuyama-shi, Japan|Research Site, Funabashi-shi, Japan|Research Site, Hamamatsu-shi, Japan|Research Site, Hirosaki-shi, Japan|Research Site, Ise-shi, Japan|Research Site, Kagoshima-shi, Japan|Research Site, Koriyama-shi, Japan|Research Site, Kumamoto-shi, Japan|Research Site, Kunitachi-shi, Japan|Research Site, Minato-ku, Japan|Research Site, Nagoya-shi, Japan|Research Site, Oita-shi, Japan|Research Site, Otsu-shi, Japan|Research Site, Oyama-shi, Japan|Research Site, Sapporo-shi, Japan|Research Site, Sendai-shi, Japan|Research Site, Shinjyuku-ku, Japan|Research Site, Suita-shi, Japan|Research Site, Tama-shi, Japan|Research Site, Tsukuba-shi, Japan|Research Site, Yokohama-shi, Japan
|
